2 results
Approved WMOCompleted
Primary Objective:- To evaluate the efficacy of PF-04360365 (ponezumab) in subjects with probableCAA as compared to placebo on a BOLD fMRI measure of cerebrovascularreactivity.Secondary Objectives:- To evaluate the efficacy of PF-04360365 (ponezumab…
Approved WMORecruiting
Does single subcutaneous injection with denosumab or placebo (NACL 0.9%) induces a shorter Total contact cast treatment duration and faster bonefracture healing (days) and does it prevent deformation of the foot in patients with Charcot foot